Member access

4-Traders Homepage  >  Shares  >  Nyse MKT  >  CEL-SCI Corporation    CVM   US1508375086

SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

CEL SCI : Secures OK to Conduct Its Phase 3 Multikine Trial in Italy

05/22/2015 | 02:53am US/Eastern

CEL-SCI Corp. reported that the Italian Medicines Agency (AIFA) has authorized the Company to commence patient enrollment for its ongoing Phase 3 trial of its investigational immunotherapy Multikine (Leukocyte Interleukin, Injection) in patients with advanced primary squamous cell carcinoma of the oral cavity/soft palate, a type of head and neck cancer.

The company said that Italy is the 23rd country to authorize CEL- SCI's Phase 3 trial for patient enrollment.

According to a release, having surpassed its originally planned milestone of receiving authorization to conduct the Phase 3 study from 21 countries, CEL-SCI is now aiming to expand the trial into a total of approximately 100 clinical centers in about 25 countries. As of April 30, 437 patients had been enrolled in the global Phase 3 study.

The Multikine Phase 3 study is enrolling patients with advanced primary squamous cell carcinoma of the head and neck. The objective of the study is to demonstrate a statistically significant improvement in the overall survival of enrolled patients who are treated with the Multikine treatment regimen plus standard of care (SOC) vs. subjects who are treated with SOC only.

Multikine (Leukocyte Interleukin, Injection) is an investigational immunotherapeutic agent that is being tested in an open-label, randomized, controlled, global pivotal Phase 3 clinical trial as a potential first-line treatment for advanced primary squamous cell carcinoma of the head and neck. Multikine is designed to be a different type of therapy in the fight against cancer: one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine is also being tested in a Phase 1 study under a Cooperative Research and Development Agreement (CRADA) with the U.S. Naval Medical Center, San Diego, as a potential treatment for peri- anal warts in HIV/HPV co-infected men and women. CEL-SCI has also entered into two co-development agreements with Ergomed Clinical Research Limited to further the development of Multikine for cervical dysplasia/neoplasia in women who are co-infected with HIV and HPV and for peri-anal warts in men and women who are co- infected with HIV and HPV.

More information:

www.cel-sci.com

((Comments on this story may be sent to newsdesk@closeupmedia.com))

(c) 2015 ProQuest Information and Learning Company; All Rights Reserved., source Trade Publications

React to this article
Latest news on CEL-SCI CORPORATION
05/22 CEL SCI : Secures OK to Conduct Its Phase 3 Multikine Trial in Italy
05/21 CEL SCI : NEW STORY CEL-SCI Announces Proposed Public Offering of Common Stock a..
05/21 CEL SCI : Announces Proposed Public Offering of Common Stock and Warrants
05/20 CEL SCI : Receives Authorization to Conduct Its Phase 3 Multikine Trial in Italy
05/18 CEL SCI : Gets OK to Conduct Its Phase 3 Multikine Trial in Italy
05/14 CEL SCI : Announces Proposed Public Offering of Common Stock
05/14 CEL SCI : Announces Proposed Public Offering of Common Stock
05/14 CEL SCI : Posts 2Q Fiscal Year 2015 Financial Results
05/13 CEL SCI : NEW STORY CEL-SCI Receives Authorization to Conduct Its Phase 3 Multik..
05/13 CEL SCI : Receives Authorization to Conduct Its Phase 3 Multikine Trial in Italy
Advertisement
Chart
Duration : Period :
CEL-SCI Corporation Technical Analysis Chart | CVM | US1508375086 | 4-Traders
Income Statement Evolution
More Financials